Bank of America Corp DE Has $574,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Bank of America Corp DE reduced its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 63.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,975 shares of the biotechnology company's stock after selling 110,715 shares during the quarter. Bank of America Corp DE's holdings in Aurinia Pharmaceuticals were worth $574,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in AUPH. Invesco Ltd. raised its stake in Aurinia Pharmaceuticals by 1.0% during the 4th quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company's stock valued at $1,294,000 after purchasing an additional 1,421 shares during the period. Teacher Retirement System of Texas lifted its holdings in Aurinia Pharmaceuticals by 5.9% in the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 2,020 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after buying an additional 2,635 shares during the period. SBI Securities Co. Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $25,000. Finally, MetLife Investment Management LLC increased its position in Aurinia Pharmaceuticals by 3.5% in the 4th quarter. MetLife Investment Management LLC now owns 85,680 shares of the biotechnology company's stock worth $769,000 after buying an additional 2,918 shares during the period. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ AUPH traded down $0.05 during mid-day trading on Friday, hitting $8.18. The company's stock had a trading volume of 942,470 shares, compared to its average volume of 1,335,582. Aurinia Pharmaceuticals Inc. has a one year low of $5.15 and a one year high of $10.67. The company's fifty day simple moving average is $7.97 and its 200-day simple moving average is $8.25. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -54.53 and a beta of 1.15.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. The company had revenue of $62.47 million for the quarter, compared to analysts' expectations of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. On average, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 earnings per share for the current fiscal year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.